The original success of Sildenafil undeniably reshaped the pharmaceutical landscape, but betting in companies primarily reliant on generic versions presents a complex picture. Despite early earnings were substantial, the end of patents and the emergence of cheaper alternatives have diminished sales. Consequently, a thorough assessment of current re